You have to give Rep. Lloyd Doggett (D-TX) credit for being consistent. He’s one of the most determined advocates for misapplying the Bayh-Dole Act so the government can license competitors when he feels that drugs arising from federally-supported R&D aren’t “reasonably priced.” Luckily, both Republican and Democratic Administrations rejected that wrongheaded idea. But rather than being discouraged, he’s taken that philosophy to a new level.
